Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HeartSciences Inc. - Common Stock (NQ:HSCS)

3.920 -1.810 (-31.59%)
Streaming Delayed Price Updated: 12:57 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HeartSciences Inc. - Common Stock

< Previous 1 2 3 Next >
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems 
From HeartSciences Inc.
Via GlobeNewswire
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
Patent covers estimation of measures of heart function using an ECG, which are critical in the diagnosis and early detection of heart disease 
From HeartSciences Inc.
Via GlobeNewswire
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
From HeartSciences Inc.
Via GlobeNewswire
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
Further expands HeartSciences extensive patent portfolio 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Regains Compliance with Nasdaq Listing Requirements
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
Granted Indian Patent for its MyoVista® Wavelet Technology 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
Patent covers use of AI-ECG for any echo measure of diastolic function, which is crucial for heart screening and early detection of heart disease 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be Recommended 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screening 
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Adds Key Advisor to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Expands its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Appoints New Scientific Advisory Board Member
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
From Heart Test Laboratories, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.